Attitudes to chemotherapy in patients with ovarian cancer

Gynecologic Oncology

Volumn 94, Issue 2, 2004, Pages 427-435

  Penson, R T ^a   Dignan, F ^a   Seiden, M V ^a   Lee, H ^a   Gallagher, C J ^b   Matulonis, U A ^a,c   Olson, K ^a   Gibbens, I ^e   Gore, M E ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e Massachusetts Gen Hosp C ^*

Author keywords

Chemotherapy; Dana Farber Cancer Institute; Dana Farber Partners Cancer Care; DF PCC; DFCI; Ovarian cancer; Remission

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANOREXIA; ARTICLE; ATTITUDE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; EDUCATION; EPITHELIUM CELL; FATIGUE; FEMALE; HAIR LOSS; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; POPULATION RESEARCH; PRIORITY JOURNAL; RASH; UNITED KINGDOM; UNITED STATES; VOMITING;

ADULT; ATTITUDE OF HEALTH PERSONNEL; CA-125 ANTIGEN; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PALLIATIVE CARE; PATIENT ACCEPTANCE OF HEALTH CARE; PILOT PROJECTS; QUESTIONNAIRES;

EID: 3543125966     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.05.034     Document Type: Article

References (26)

1. Greenlee R.T., Murray T., Bolden S., Wingo P.A. Cancer statistics, 2000. CA Cancer J. Clin. 50:2000;7-33
2. Adams M., A'Hern R.P., Calvert A.H., et al. Chemotherapy for ovarian cancer - A consensus statement on standard practice. Br. J. Cancer. 78:1998;1404-1406
3. Berek J.S., Bertelsen K., du Bois A., et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann. Oncol. 10(Suppl. 1):1999;87-92
4. Penson R.T., Shannon K.E., Sharpless N.E., Seiden M.V. Ovarian cancer: an update on genetics and therapy. Compr. Ther. 24:1998;477-487
5. Bast R.C. Jr., Ritz J., Lipton J.M., et al. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res. 43:1983;1389-1394
6. Niloff J.M., Knapp R.C., Lavin P.T., et al. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am. J. Obstet. Gynecol. 155:1986;56-60
7. Vermorken J.B., Pecorelli S. Clinical trials in patients with epithelial ovarian cancer: past, present and future. Eur. J. Surg. Oncol. 22:1996;455-466
8. Silvestri G., Pritchard R., Welch H.G. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ. 317:1998;771-775
9. Slevin M.L., Stubbs L., Plant H.J., et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ. 300:1990;1458-1460
10. Cooper S., Georgiou V. The impact of cytotoxic chemotherapy-perspectives from patients, specialists and nurses. Eur. J. Cancer. 28A:1992;S36-S38
11. Damrosch S., Denicoff A.M., St Germain D., et al. Oncology nurse and physician attitudes toward aggressive cancer treatment. Cancer Nurs. 16:1993;107-112
12. Piga A., Graziano F., Zahra G., Cellerino R. Attitudes of non-oncology physicians dealing with cancer patients. A survey based on clinical scenarios in Ancona province, central Italy. Tumori. 82:1996;423-429
13. Bremnes R.M., Andersen K., Wist E.A. Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur. J. Cancer. 31A:1995;1955-1959
14. Mackillop W.J., O'Sullivan B., Ward G.K. Non-small cell lung cancer: how oncologists want to be treated. Int. J. Radiat. Oncol. Biol. Phys. 13:1987;929-934
15. Moinpour C.M. Measuring quality of life: an emerging science. Semin. Oncol. 21:1994;48-60. [discussion 60-3]
16. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14:1996;1756-1764
17. Lamont E.B., Christakis N.A. Physician factors in the timing of cancer patient referral to hospice palliative care. Cancer. 94:2002;2733-2737
18. Harries M., Gore M. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol. 3:2002;537-545
19. Extermann M., Albrand G., Chen H., et al. Are older French patients as willing as older American patients to undertake chemotherapy? J. Clin. Oncol. 21:2003;3214-3219
20. Goodman A., Houck K. Anxiety and uncertainty in informed decision making. J. Womens Health Gend. Based Med. 10:2001;93-94
21. Emanuel E.J., Young-Xu Y., Levinsky N.G., Gazelle G., Saynina O., Ash A.S. Chemotherapy use among Medicare beneficiaries at the end of life. Ann. Intern. Med. 138:2003;639-643
22. Kaye S.B., Vasey P.A. Docetaxel in ovarian cancer: phase III perspectives and future development. Semin. Oncol. 29:2002;22-27
23. Parmar M.K., Ledermann J.A., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 361:2003;2099-2106
24. Kornblith A.B., Thaler H.T., Wong G., et al. Quality of life of women with ovarian cancer. Gynecol. Oncol. 59:1995;231-242
25. De Haes J., Raatgever J., van der Burg M. Evaluation of the quality of life of patients with advanced ovarian cancer treated with combination chemotherapy. Aronson N., Beckmann J. The quality of life of cancer patients. 1987;215-227 Raven Press, New York
26. Doyle C., Crump M., Pintilie M., Oza A.M. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J. Clin. Oncol. 19:2001;1266-1274